TRIM21 and Sensorimotor neuropathy: We found that patients with sensorimotor neuropathy had longer disease duration (5,82 ± 3,82 versus 1,67 ± 1,07 p < .05), more of them had anti‐SS‐A antibodies (91% vs. 50% p < .05), hypocomplementemia (55% vs. 0% p < .05), hypergammaglobulinemia (82% vs. 33% p < .05), and elevated levels of B‐2‐microglobulin (91% vs. 17% p < .05).